

Millendo Therapeutics, Inc. Logo

## Millendo Therapeutics to Participate in September Investor Conferences

August 29, 2019

ANN ARBOR, Mich.--(BUSINESS WIRE)--Aug. 29, 2019-- [Millendo Therapeutics, Inc.](#) (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that senior management will present company overviews and conduct one-on-one investor meetings at the following healthcare investor conferences:

### **Citi's 14th Annual Biotech Conference**

Date: Thursday, September 5, 2019 (one-on-one meetings only)

Location: Boston, MA

### **Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies**

Date: Monday, September 23, 2019 (one-on-one meetings only)

Location: New York, NY

### **Ladenburg Thalmann 2019 Healthcare Conference**

Date/Time: Tuesday, September 24, 2019 at 11:00 a.m. EDT

Location: New York, NY

A live webcast of theLadenburg Thalmann presentation will be available on the Investors & Media section of Millendo's website at <http://investors.millendo.com>. A replay of the webcast will be archived on Millendo's website for 30 days following the presentation.

### **About Millendo Therapeutics, Inc.**

Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome, nevanimibe for the treatment of classic congenital adrenal hyperplasia and MLE-301 for the treatment of vasomotor symptoms associated with menopause. For more information, please visit [www.millendo.com](http://www.millendo.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190829005139/en/>

Source: Millendo Therapeutics, Inc.

### **Millendo Investor Contact:**

Stephanie Ascher

Stern Investor Relations

212-362-1200

[stephanie.ascher@sternir.com](mailto:stephanie.ascher@sternir.com)

### **Millendo Media Contact:**

Betsy Yates

MacDougall

781-235-3094

[byates@macbiocom.com](mailto:byates@macbiocom.com)